85723-72-4

Basic information

• Product Name: 3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE
• Synonyms: 3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE;2,6-dimethyl-1-piperidinepropanamine
• CAS NO: 85723-72-4
• Molecular Formula: C10H22N2
• Molecular Weight: 170.3
• Mol File: 85723-72-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 222.1 °C at 760 mmHg
• Flash Point: 86.3 °C
• Appearance: /
• Density: 0.872 g/cm³
• Vapor Pressure: 0.103mmHg at 25°C
• CAS DataBase Reference: 3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE(85723-72-4)
• EPA Substance Registry System: 3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE(85723-72-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 85723-72-4(Hazardous Substances Data)

Usage

General Description

3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE is a chemical compound with the molecular formula C11H24N2. It is an organic amine that contains a piperidine ring and a propylamine group. 3-(2,6-DIMETHYL-PIPERIDIN-1-YL)-PROPYLAMINE is commonly used in the synthesis of pharmaceuticals and other organic molecules due to its ability to serve as a building block for larger, more complex compounds. It may also have potential applications in the field of medicinal chemistry and drug development. Additionally, its unique chemical structure and properties make it a valuable tool for organic chemists in the development of new chemical compounds.

InChI:InChI=1/C10H22N2/c1-9-5-3-6-10(2)12(9)8-4-7-11/h9-10H,3-8,11H2,1-2H3/p+2/t9-,10-/m1/s1

Upstream product

• 65480-91-3 3-<1-(2,6-dimethyl)piperidinyl>propanenitrile 
• 766-17-6 (2R,6S)-2,6-dimethylpiperidine 
• 88981-94-6 trans-2,6-dimethyl-1-piperidinepropanenitrile 
• 10066-29-2 trans-2,6-dimethylpiperidine 

Relevant articles and documents

Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of 7ii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.

Super high specific activity tritium labelled receptor ligands - 1. The use of polybromodiphenylacetic acid as a tritiation substrate. Synthesis of a tritium labelled sodium-channel blocker and angiotensin ii antagonist with super high specific activity

We describe herein the synthesis of polybromodiphenylacetic acid (4), a fragment common to the tritiation substrates (8) and (11) of the sodium channel blocker, PD-85639 (1) and the angiotensin II inhibitor EXP-655 (2) respectively. Preparation of (8) and

Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl]-2-oxo-1-pyrrolidineacetamides, including pramiracetam

A series of N-[(dialkylamino)alkyl]-2-oxo-1-pyrrolidineacetamides was synthesized. The title compounds reversed electroconvulsive shock (ECS) induced amnesia in mice when administered subsequent to the ECS treatment and were inactive in a general observational test for central nervous system (CNS) activity. Active compounds exhibited an inverted U-shaped dose-response curve. Among the compounds with the broadest dose-response curve, as well as the most potent, were those with the N-[2-[bis(1-methylethyl)amino]ethyl] or 2,6-dimethylpiperidinoethyl residues as amide substituent. The N-(dialkylamino) substituent markedly enhances amnesia-reversal activity, with ethylene providing the optimal chain length. N-[2-[Bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide N(-dialkylamino) substituent was selected for preclinical toxicological evaluation, assigned the investigational number CI-879 and the U.S. adopted name (USAN) pramiracetam. Pramiracetam demonstrated a wide margin of safety in animals and was tolerated in normal human volunteers. It has shown encouraging activity in an open label trial in patients with primary degenerative dementia (PDD or senile dementia of the Alzheimer's type).